IMBiotechnologies
AB - EdmontonBiotechnology
Focus: IMBiotechnologies develops embolotherapy devices focused on women's health applications, specifically uterine fibroids and benign prostatic hyperplasia. The company is a private, early-stage biotech founded in 2008 based in Edmonton, Alberta.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About IMBiotechnologies
AI assessmentNot HiringNo open roles listed right now. Follow IMBiotechnologies to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Embolization of prostatic artery under ultrasound guidance
Benign Prostatic HyperplasiaClinical Trials (1)
NCT04267445Evaluate the Safety and Effectiveness of Using Echogenic Embolic Agent for Embolization of Prostate Artery for Treatment of Men With BPH (PAE CEUS)
N/AHelp build intelligence for IMBiotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.